Primary and residual cardiometabolic risk factors among young adults in a Russian city.
Cardiometabolic disease staging
Cardiometabolic risk factors
Dysglycemia
Dyslipidemia
Hypertension
Obesity
Prediabetes
Journal
Journal of health, population, and nutrition
ISSN: 2072-1315
Titre abrégé: J Health Popul Nutr
Pays: Bangladesh
ID NLM: 100959228
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
05
06
2024
accepted:
05
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
Cardiovascular diseases are a leading cause of mortality and a significant contributor to temporary and permanent disabilities worldwide. This study aimed to investigate the burden of primary and residual cardiometabolic risk factors in a sample of young adults in the Russian city of Kazan. This case-control study used the Cardiometabolic Disease Staging (CMDS) classification system, which has been validated in several countries. The study included 191 individuals aged 25-44 years who met the inclusion criteria but did not meet any exclusion criteria. Data collection involved a patient card with questions from the World Health Organization's STEPS instrument, face-to-face patient interviews, and a physical examination. Anthropometric assessments included height, weight, and waist circumference measurements. Body composition was evaluated using bioelectrical impedance measurements. Patients also underwent in-depth laboratory biochemical analyses. The study cohort was comprised of 97 females (50.8%) and 94 males (49.2%). The median age of participants was 35.00 years [IQR: 30.00-39.00]. The study cohort showed an increase in all anthropometric parameters, with abdominal obesity and overweight reaching 100% in the CMDS 3. Apart from atherogenic lipids and raised blood pressure, other risk factors that precipitate residual risk and were not part of CMDS, such as insulin levels, insulin resistance, leptin values, and hyperuricemia, increased as CMDS levels increased. The prevalence of cardiometabolic risk factors was high in young adults in Kazan. This study highlights the need for the early identification and management of cardiometabolic risk factors in young adults to prevent the development of cardiovascular diseases later in life.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiovascular diseases are a leading cause of mortality and a significant contributor to temporary and permanent disabilities worldwide. This study aimed to investigate the burden of primary and residual cardiometabolic risk factors in a sample of young adults in the Russian city of Kazan.
METHODS
METHODS
This case-control study used the Cardiometabolic Disease Staging (CMDS) classification system, which has been validated in several countries. The study included 191 individuals aged 25-44 years who met the inclusion criteria but did not meet any exclusion criteria. Data collection involved a patient card with questions from the World Health Organization's STEPS instrument, face-to-face patient interviews, and a physical examination. Anthropometric assessments included height, weight, and waist circumference measurements. Body composition was evaluated using bioelectrical impedance measurements. Patients also underwent in-depth laboratory biochemical analyses.
RESULTS
RESULTS
The study cohort was comprised of 97 females (50.8%) and 94 males (49.2%). The median age of participants was 35.00 years [IQR: 30.00-39.00]. The study cohort showed an increase in all anthropometric parameters, with abdominal obesity and overweight reaching 100% in the CMDS 3. Apart from atherogenic lipids and raised blood pressure, other risk factors that precipitate residual risk and were not part of CMDS, such as insulin levels, insulin resistance, leptin values, and hyperuricemia, increased as CMDS levels increased.
CONCLUSIONS
CONCLUSIONS
The prevalence of cardiometabolic risk factors was high in young adults in Kazan. This study highlights the need for the early identification and management of cardiometabolic risk factors in young adults to prevent the development of cardiovascular diseases later in life.
Identifiants
pubmed: 39444051
doi: 10.1186/s41043-024-00658-5
pii: 10.1186/s41043-024-00658-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
166Informations de copyright
© 2024. The Author(s).
Références
Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet. 2020;396:1204–22.
doi: 10.1016/S0140-6736(20)30925-9
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J Am Coll Cardiol. 2020;76:2982–3021.
doi: 10.1016/j.jacc.2020.11.010
pubmed: 33309175
pmcid: 7755038
Mensah GA, Fuster V, Murray CJL, Roth GA, Mensah GA, Abate YH, et al. Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol. 2023;82:2350–473.
doi: 10.1016/j.jacc.2023.11.007
pubmed: 38092509
pmcid: 7615984
Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers. J Am Coll Cardiol. 2020;75:525–38.
doi: 10.1016/j.jacc.2019.11.044
pubmed: 32029136
pmcid: 7187687
Vilkov VG, Shalnova SA. Thirty-year trends in the prevalence of cardiometabolic risk factors in the populations of the Russian Federation and the United States of America. Cardiovasc Therapy Prev. 2022;21:3304.
doi: 10.15829/1728-8800-2022-3304
Nawsherwan MS, Bin W, Le Z, Sang M, Lin Y, et al. Epidemiological trends in cardiovascular disease mortality attributable to modifiable risk factors and its association with sociodemographic transitions across BRICS-plus countries. Nutrients. 2023;15:3757.
doi: 10.3390/nu15173757
pubmed: 37686788
pmcid: 10489729
Shi S, Huang H, Huang Y, Zhong VW, Feng N. Lifestyle behaviors and cardiometabolic diseases by race and ethnicity and social risk factors among US young adults, 2011 to 2018. J Am Heart Assoc. 2023;12.
Tahir UA, Gerszten RE. Molecular biomarkers for cardiometabolic disease: risk assessment in young individuals. Circ Res. 2023;132:1663–73.
doi: 10.1161/CIRCRESAHA.123.322000
pubmed: 37289904
pmcid: 10320574
Sineglazova AV, Fakhrutdinova AS, Parve SD, Nurieva AR, Mustafina GR. Dyslipidemiа as an important dominant of cardiometabolic risk in young aged people. Mod Probl Sci Educ (Sovremmenyie problemy nauki i obraozvaniya). 2023;2:85.
Ponte-Negretti CI, Wyss F, Piskorz D, Santos RD, Villar R, Lorenzatti A et al. Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and cardiometabolic risk (ALALIP) endorsed by the Inter-american Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the pan-american college of endothelium (PACE). Arch Cardiol Mex. 2021;92.
Cosentino F, Verma S, Ambery P, Treppendahl MB, van Eickels M, Anker SD, et al. Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round table. Eur Heart J. 2023;44:4141–56.
doi: 10.1093/eurheartj/ehad445
pubmed: 37448181
Singh A, Bruemmer D. Cardiometabolic Risk. JACC: Adv. 2024;3:100867.
pubmed: 38939673
Howell CR, Zhang L, Mehta T, Wilkinson L, Carson AP, Levitan EB, et al. Cardiometabolic disease staging and major adverse cardiovascular event prediction in 2 prospective cohorts. JACC: Adv. 2024;3:100868.
pubmed: 38765187
Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity. 2014;22:110–8.
doi: 10.1002/oby.20585
pubmed: 23894121
Polcrova A, Pavlovska I, Maranhao Neto GA, Kunzova S, Infante-Garcia MM, Medina-Inojosa JR, et al. Visceral fat area and cardiometabolic risk: the Kardiovize study. Obes Res Clin Pract. 2021;15:368–74.
doi: 10.1016/j.orcp.2021.03.005
pubmed: 33744224
Nieto-Martínez R, González-Rivas JP, Ugel E, Brajkovich I, Risquez A, Garvey WT, et al. Application of the AACE/ACE advanced framework for the diagnosis of obesity and cardiometabolic disease staging in a general population from 3 regions of Venezuela: the Vemsols study results. Endocr Pract. 2018;24:6–13.
doi: 10.4158/EP161644.OR
pubmed: 29106817
Hirose K, Nakanishi K, Daimon M, Sawada N, Yoshida Y, Iwama K, et al. Impact of insulin resistance on subclinical left ventricular dysfunction in normal weight and overweight/obese Japanese subjects in a general community. Cardiovasc Diabetol. 2021;20:22.
doi: 10.1186/s12933-020-01201-6
pubmed: 33478525
pmcid: 7818760
Li J-J, Liu H-H, Li S. Landscape of cardiometabolic risk factors in Chinese population: a narrative review. Cardiovasc Diabetol. 2022;21:113.
doi: 10.1186/s12933-022-01551-3
pubmed: 35729555
pmcid: 9215083
Balanova YA, Kapustina AV, Shalnova SA, Imaeva AE, Muromtseva GA, Evstifeeva SE, et al. Behavioral risk factors in the Russian population: results of a survey using a modified methodology STEPS. Profilakticheskaya Meditsina. 2020;23:56.
doi: 10.17116/profmed20202305156
Bonita R, Winkelmann R, Douglas KA, De Courten J. The WHO stepwise approach to surveillance (STEPS) of non-communicable disease risk factors. In: McQueen D, Puska P, editors. Global behavioural risk factor surveillance. New York: Kluwer Academic; 2003. pp. 9–22.
doi: 10.1007/978-1-4615-0071-1_3
Tanita. Instruction manual for InnerScan V segmental body composition monitor, BC–601, Tanita publication, Japan. https://www.manualslib.com/manual/2723866/Tanita-Innerscan-V-Bc-601.html . Accessed 31 May 2024.
World Health Organization (WHO). Body mass index - BMI. 2010. http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi . Accessed 31 May 2024.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2022;29:5–115.
doi: 10.1093/eurjpc/zwab154
pubmed: 34558602
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
doi: 10.1093/eurheartj/ehz486
pubmed: 31497854
Kidney Disease. Improving global outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205.
doi: 10.1016/j.atherosclerosis.2019.08.014
Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral adiposity index. Diabetes Care. 2010;33:920–2.
doi: 10.2337/dc09-1825
pubmed: 20067971
pmcid: 2845052
Jia A, Xu S, Ming J, Xing Y, Guo J, Zhao M, et al. Body fat percentage cutoffs for risk of cardiometabolic abnormalities in the Chinese adult population: a nationwide study. Eur J Clin Nutr. 2018;72:728–35.
doi: 10.1038/s41430-018-0107-0
pubmed: 29410481
Shlyakhto EV, Nedogoda SV, Konradi AO, Baranova EI, Fomin VV, Vertkin AL et al. The concept of novel national clinical guidelines on obesity. Russian J Cardiol. 2016;4:7–13.
Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2021;143:e984–1010.
doi: 10.1161/CIR.0000000000000973
pubmed: 33882682
pmcid: 8493650
Perakakis N, Farr OM, Mantzoros CS. Leptin in leanness and obesity. J Am Coll Cardiol. 2021;77:745–60.
doi: 10.1016/j.jacc.2020.11.069
pubmed: 33573745
pmcid: 8483570
Mustafina SV, Denisova DV, Alferova VI, Shramko VS, Shcherbakova LV. Leptin and cardiometabolic risk factors in overweight persons in young age. Ateroscleroz. 2021;17:51–60.
doi: 10.52727/2078-256X-2021-17-2-51-60
Balanova YA, Shalnova SA, Imaeva AE, Kapustina АV, Muromtseva GA, Evstifeeva SV, et al. Prevalence, awareness, treatment and control of hypertension in Russian Federation (Data of Observational ESSERF-2 study). Ration Pharmacotherapy Cardiol. 2019;15:450–66.
doi: 10.20996/1819-6446-2019-15-4-450-466
Zhao L, Meng X, Zhang Q-Y, Dong X-Q, Zhou X-L. A narrative review of prehypertension and the cardiovascular system: effects and potential pathogenic mechanisms. Ann Transl Med. 2021;9:170–170.
doi: 10.21037/atm-20-5482
pubmed: 33569472
pmcid: 7867937
Bakhtiyari M, Kazemian E, Kabir K, Hadaegh F, Aghajanian S, Mardi P, et al. Contribution of obesity and cardiometabolic risk factors in developing cardiovascular disease: a population-based cohort study. Sci Rep. 2022;12:1544.
doi: 10.1038/s41598-022-05536-w
pubmed: 35091663
pmcid: 8799723
Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, addressing knowledge and clinical practice gaps. J Am Coll Cardiol. 2020;75:539–55.
doi: 10.1016/j.jacc.2019.11.046
pubmed: 32029137
pmcid: 8168371
Guo F, Garvey WT. Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults. Obesity. 2016;24:516–25.
doi: 10.1002/oby.21344
pubmed: 26719125
Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obes (Silver Spring). 2014;22:110–8.
doi: 10.1002/oby.20585
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–82.
doi: 10.1016/S0140-6736(09)60447-5
pubmed: 19329177
Alfaddagh A, Martin SS, Leucker TM, Michos ED, Blaha MJ, Lowenstein CJ, et al. Inflammation and cardiovascular disease: from mechanisms to therapeutics. Am J Prev Cardiol. 2020;4:100130.
doi: 10.1016/j.ajpc.2020.100130
pubmed: 34327481
pmcid: 8315628
Reinmann M, Meyer P. B-type natriuretic peptide and obesity in heart failure: a mysterious but important association in clinical practice. Cardiovasc Med. 2020;23:w02095.
Echouffo-Tcheugui JB, Zhang S, McEvoy JW, Juraschek SP, Fang M, Ndumele CE, et al. Insulin resistance and N-Terminal Pro-B-Type natriuretic peptide among healthy adults. JAMA Cardiol. 2023;8:989.
doi: 10.1001/jamacardio.2023.2758
pubmed: 37672260
pmcid: 10483384
Ahued-Ortega JA, León-García PE, Hernández-Pérez E. Correlación De Los Niveles plasmáticos Del péptido natriurético tipo B con marcadores de riesgo metabólico. Med Clin (Barc). 2018;151:481–6.
doi: 10.1016/j.medcli.2018.02.009
pubmed: 29678316
Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol. 2004;43:1590–5.
doi: 10.1016/j.jacc.2003.10.066
pubmed: 15120816
Al Shanableh Y, Hussein YY, Saidwali AH, Al-Mohannadi M, Aljalham B, Nurulhoque H, et al. Prevalence of asymptomatic hyperuricemia and its association with prediabetes, dyslipidemia and subclinical inflammation markers among young healthy adults in Qatar. BMC Endocr Disord. 2022;22:21.
doi: 10.1186/s12902-022-00937-4
pubmed: 35031023
pmcid: 8760639